The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of β1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of β1 integrin. The present ...
Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody That Targets Two Distinct Epitopes on αv Integrins which we used as biparatopic building blocks to construct a bispecific antibody that strongly inhibited integrin function and may be a therapeutic candidate ... ...
28. A method for reducing levels of β-amyloid in the brain of an animal, comprising the steps: a) providing vectorized bispecific antibodies competent to transcytose across the blood brain barrier, which catalyze hydrolysis of β-amyloid of the animal at a predetermined amide linkage; and b)...
In some embodiments, the antibodies and antigen-binding fragments of the invention may have: (1) a dissociation constant (Kd) of less than or equal to 1 nM for human proTGFβ1 in a complex with human glycoprotein A repetitions predominant (proTGFβ1-GARP complex) in solution; (2) an in...
The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of β1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of β1 integrin. The present ...
The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of β1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of β1 integrin. The present ...
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin 卤51 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and ...
The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of β1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of β1 integrin. The present ...
The present invention describes a bispecfic antibody composed of the variable\ndomains (VH and VL) of two antibodies,\nhERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of (.beta.1\nintegrin mAb TS2/16 or BV7, which bind the extracellular\ndomain of (.beta.1 ...
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and ...